Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 7681 results

  1. Duplicate

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  3. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

    In development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  5. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ranibizumab port delivery system for treating diabetic macular oedema ID6137

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

    Technology appraisal guidance
    Awaiting development

  8. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Osteoporosis

    Awaiting development [GID-QS10188] Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  12. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Benralizumab for previously treated severe nasal polyps [ID1659]

    Awaiting development [GID-TA10818] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development [GID-TA11307] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development